α-Galactosylceramide enhances the protective and therapeutic effects of tumor cell based vaccines for ovarian tumors

Youn Seok Choi, Talia Hoory, Archana Monie, Annie Wu, Denise Connolly, Chien Fu Hung

Research output: Contribution to journalArticlepeer-review

Abstract

Ovarian cancer is one of the leading causes of death from gynecological cancers in the United States. Conventional therapies are unlikely to control advanced stage ovarian cancers, thus requiring innovative alternative therapies. In the current study, we characterized the therapeutic effect of tumor cell-based vaccines combined with the adjuvant, α-galactosylceramide (α-GalCer) using two different mouse models. Our data suggests that treatment with α-GalCer led to an increase in the IFN-γ serum levels in the presence or absence of irradiated mouse ovarian surface epithelial tumor cells (MOSEC). Furthermore, administration of irradiated MOSEC tumor cells with adjuvant α-GalCer generated significant protective and therapeutic antitumor effects against MOSEC tumors in vaccinated C57BL/6 mice. In addition, immune cells expressing CD4, CD8 or NK1.1 markers were found to be important for the protective antitumor effects generated by irradiated tumor cell-based vaccines combined with adjuvant α-GalCer. We also found that treatment of a spontaneous ovarian cancer murine model, the Müllerian inhibiting substance type II receptor T antigen (TgMISIIR-TAg) transgenic mice with ovarian tumor cell-based vaccines combined with adjuvant α-GalCer led to prolonged survival as well as increased numbers of tumor-specific CD8+ T cells. Therefore, irradiated tumor cell-based vaccines in combination with α-GalCer are capable of breaking immune tolerance and generating significant antitumor effects in two different mouse tumor models. Our study serves as a foundation for future clinical translation.

Original languageEnglish (US)
Pages (from-to)5855-5863
Number of pages9
JournalVaccine
Volume26
Issue number46
DOIs
StatePublished - Oct 29 2008

Keywords

  • Adjuvant
  • MOSEC
  • Ovarian
  • Tumor cell-based vaccines
  • α-Galactosylceramide

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Fingerprint Dive into the research topics of 'α-Galactosylceramide enhances the protective and therapeutic effects of tumor cell based vaccines for ovarian tumors'. Together they form a unique fingerprint.

Cite this